Inquirer on MSN1d
World’s first anti-depression nasal spray receives FDA approval
The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more potent ...
BioSpace1d
GH’s Inhaled Psychedelic Succeeds in Mid-Stage Depression Trial
In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...
News on 62d
FDA expands approval for antidepressant nasal spray
The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...
Hosted on MSN4d
FDA approves 'ketamine' nasal spray for depression — here's everything you need to know
A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...
KADN4d
Covering Your Health: New depression drug offers hope
For those with major depression, there is a new treatment option - one that offers hope when patients are not responding to existing treatment. The ...
psychiatryadvisor.com6d
Spravato Approved as Monotherapy for Treatment-Resistant Depression
The FDA has approved Spravato (esketamine) nasal spray for use as monotherapy for patients with treatment-resistant depression.
BioSpace6d
Atai Touts Positive Data for Psychedelic Therapy in Alcohol Use Disorder
The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...